Search

Displaying results 4941 - 4950 of 10000 in total
  1. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

    Categories: Calcium-Regulating Hormones and Agents, Metabolic Side Effects of Drugs and Substances
  2. Drug

    ACA 125

    go.drugbank.com/drugs/DB05489
    Investigational

    ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas. … An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies.

  3. Drug

    Repinotan

    go.drugbank.com/drugs/DB06506
    Investigational

    Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

  4. Drug

    Androstenedione

    go.drugbank.com/drugs/DB01536
    IllicitInvestigational

    A delta-4 C19 steroid that is produced not only in the testis, but also in the ovary and the adrenal cortex. … Depending on the tissue type, androstenedione can serve as a precursor to testosterone as well as estrone and estradiol.

    Categories: Hormones, Hormone Substitutes, and Hormone Antagonists
  5. Drug

    Laropiprant

    go.drugbank.com/drugs/DB11629
    ApprovedWithdrawn

    Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

  6. Drug

    Gremubamab

    go.drugbank.com/drugs/DB15014
    Investigational

    Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).

    Categories: Amino Acids, Peptides, and Proteins
  7. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU. … Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing

    Categories: Nucleic Acids, Nucleotides, and Nucleosides
  8. Drug

    Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10799
    ApprovedInvestigational

    Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … grown in another culture.

  9. Drug

    Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10800
    ApprovedInvestigational

    Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … grown in another culture.

  10. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    [L63927] Gedatolisib was approved by the FDA on July 14, 2026, in combination with [fulvestrant], with or without [palbociclib], for adults with HR-positive, HER2-negative locally advanced or metastatic … Gedatolisib is a kinase inhibitor that blocks all four class I PI3K isoforms together with both mTOR complexes, mTORC1 and mTORC2, producing downstream inhibition of multiple effectors including AKT.

    Categories: Antineoplastic and Immunomodulating Agents, Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors